The United States has said it will speed up approval for some generic drugs. The development comes weeks after it was reported that the Trump administration had dropped its plans to impose tariffs on ...

The U.S. Food and Drug Administration will take steps to streamline the process to develop generic versions of complex ...

The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative ...

It's the Trump administration's latest move to rein in high prescription drug costs in the U.S., and could be a blow to pharmaceutical companies.

The "The FDA (Food and Drug Administration) Drug Approval Process Training Course (Feb 23rd - Feb 24th, 2026)" training has been added to ResearchAndMarkets.com's offering.

The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the ...

There are three obstacles to faster development and deployment of non-addictive pain treatments. They are the business environment, the regulatory environment, and the reimbursement environment.

US FDA moves to accelerate biosimilar development and lower drug costs: Maryland Friday, October 31, 2025, 14:00 Hrs [IST] The US Food and Drug Administration (FDA) announced sign ...

For Indian pharmaceutical companies that already supply nearly half of all generic medicines sold in the US, the decision signals faster market access and potentially higher export volumes.

Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive ...

Biologic medications, while accounting for only 5% of U.S. prescriptions, represent 51% of total drug spending in 2024. Despite FDA-approved biosimilars being as safe and effective as their branded ...

WASHINGTON - The Food and Drug Administration announced Wednesday that it plans to streamline the approval process for cheaper, "biosimilar" alternatives to biologic drugs in an effort to reduce ...